Novel intranasal vaccine strategies against respiratory viruses
Systemic vaccines against respiratory viruses such as influenza or SARS-CoV-2 are very efficient to protect from severe diseases. However, they are less efficient against infection. In addition to the evolution of viruses, a weakness is the low and/or short-term mucosal responses induced by systemic vaccination. Intranasal vaccination is a way to improve respiratory responses. We will develop a novel intranasal vaccine platform against respiratory viruses.
Characterization of tissue-resident memory responses in mucosal tissues
One of main challenge of mucosal vaccination including intranasal vaccination, is to induce long-term mucosal memory responses. Mucosal tissue-resident memory T and B cells have shown to be key in long-term protection at mucosal surfaces. We will characterize tissue-resident memory T and B cells induced by respiratory infections.
Adjuvants to induce mucosal tissue-resident memory responses
We will tailor our intranasal vaccine strategies to enhance the development and maintenance of tissue-resident memory T and B cells in airway tissues. We will also screen adjuvants which can improve tissue-resident memory responses in airway tissues.
Projects in collaboration with companies
"You always learn more from an experiment that goes wrong than you do from an experiment that goes right" (Sir Harold Kroto, Nobel Prize in Chemistry, 1996)